KAWASAKI, Japan, Jan 26, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced the launch of a dedicated AI platform that allows enterprises to autonomously manage the entire generative AI lifecycle, including optimal model development, operation, and incremental learning as well as continuous improvement of models and agents. The platform will be rolled out sequentially in Japan and Europe, with preliminary trial registration slated to begin in February 2026.Moving forward, Fujitsu will accelerate deployment of the platform for all AI scales from large enterprise AI to edge and physical AI. Fujitsu will continuously evolve generative AI to align with business changes, enabling its safe and reliable use across all industries and operations, ultimately fostering customer transformation and growth.Overview of the new platformEnterprises using generative AI need an environment that meets sovereign requirements, including the need for protection of confidential data and the ability to autonomously control AI models and agents optimized for their operations. However, deploying such an AI platform in a dedicated in-house setting faces challenges including AI engineer sta...

TOKYO, Jan 26, 2026 - (JCN Newswire via SeaPRwire.com) - Japan LEO Shachu, Inc. ("Japan LEO Shachu", Head Office: Chuo City, Tokyo, President and CEO: Yudai Yamamoto), which was established by Mitsui & Co., Ltd. ("Mitsui", Head Office: Tokyo, President and CEO: Kenichi Hori), has implemented a third-party allocation of new shares, and Mitsubishi Heavy Industries, Ltd. ("MHI", Head Office: Chiyoda City, Tokyo, President and CEO: Eisaku Ito) and Mitsubishi Electric Corporation ("Mitsubishi Electric", Head Office: Chiyoda City, Tokyo, President and CEO: Kei Uruma) have conducted their subscription and investment procedures.The International Space Station (ISS) has hitherto been developed and operated by the governments of 15 countries participating in an intergovernmental agreement. Following the planned retirement of the ISS in 2030, development and operation of space stations in the post ISS era are expected to be led by the private sector. As private-sector activities related to post-ISS accelerate, market expansion is anticipated. Japan LEO Shachu was established in July 2024 as a wholly owned subsidiary of Mitsui with the aim of creating a new economy in low Earth orbit (LEO)...

HONG KONG, January 26, 2026 - (ACN Newswire via SeaPRwire.com) – On January 22, at Geely Holding Group’s Strategy Briefing for 2026, CaoCao Inc. announced plans to deploy 100,000 fully purpose-built Robotaxis by 2030 and to launch large-scale commercial operations worldwide.CaoCao is Geely Holding Group’s primary commercial platform for Robotaxi operations and has developed a three-part model that combines “intelligent purpose-built vehicle, intelligent driving technology and intelligent operation”. This model brings together all the key elements required for Robotaxi development. CaoCao has spent the past decade cultivating the shared mobility market, accumulating vast volumes of trip data, developing mature dispatch algorithms, and building a nationwide service network, all of which provide a solid foundation for Robotaxi commercialization. In addition, by owning and operating the largest custom fleet of its kind in China, CaoCao has gained valuable experience in large-scale fleet operations and efficient asset management, directly applicable to the Robotaxi era.CaoCao’s Robotaxi 2.0 phase is currently undergoing pilot operations. The comp...

TOKYO and CAMBRIDGE, Mass., Jan 26, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai’s Supplemental Biologics License Application (sBLA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026.Should the FDA approve the LEQEMBI IQLIK 500 mg SC dosing regimen (two 250 mg injections), the autoinjector could be used to administer a once-weekly starting dose, as an alternative to the current bi-weekly intravenous (IV) dosing. This would enable patients and care partners to choose SC administration at ho...